Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
NCT01566435
Completed
This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Head and Neck Neoplasms
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
NCT01859741
Terminated
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/07/2020
Locations: Highlands Oncology Group, Rogers, Arkansas +34 locations
Conditions: Stage IV Small Cell Lung Cancer
Register for Updates
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
NCT01711515
Completed
This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as ipil... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/01/2020
Locations: Los Angeles County-USC Medical Center, Los Angeles, California +15 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Register for Updates
Biochemotherapy With Temozolomide for Metastatic Melanoma
NCT00505635
Terminated
The goal of this clinical research study is to learn if treatment with Temodar (temozolomide), Velban (vinblastine), Cisplatin, Proleukin (interleukin-2), Intron-A (interferon alpha), and thalidomide can help to control melanoma that has spread to other parts of the body. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/01/2020
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
NCT00736944
Completed
This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in patients with local regionally advanced HNSCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2020
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT02121990
Completed
The purpose of this study is to test the safety of the drug olaparib at different dose levels. It will be given with the standard initial chemotherapy for cancer as well as a drug called bevacizumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/20/2020
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
NCT00851877
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/19/2020
Locations: Baylor Research Institute, Dallas, Texas +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
NCT00514540
Completed
The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer. The side effects, characteristics of patients who respo... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/17/2020
Locations: University of California-San Francisco, San Francisco, California +1 locations
Conditions: Prostate Cancer
Register for Updates
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02784795
Completed
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2020
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +10 locations
Conditions: Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
Register for Updates
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
NCT00859495
Terminated
The primary objective of the study is to determine the feasibility (as determined by lack of serious adverse events) and tolerability (as determined by patient's ability to complete the study) of a multimodal lung sparing regimen of surgery, interpleural and intravenous chemotherapy, and local P-32 irradiation for malignant pleural mesothelioma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2020
Locations: Columbia University Medical Center, New York, New York
Conditions: Pleural Mesothelioma
Register for Updates
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
NCT01218516
Completed
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed followed by farletuzumab or placebo on investigator-assessed progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or definitive clinical disease progression (eg, new occurrence of positive fluid cytology) in chemoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2020
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +92 locations
Conditions: Adenocarcinoma of the Lung
Register for Updates
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
NCT00020787
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2020
Locations: Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates